Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT03326102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.
Study identification
- NCT ID
- NCT03326102
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2018 (Actual)
- Primary completion
- Dec 13, 2022 (Actual)
- Completion
- Dec 13, 2022 (Actual)
- Last update posted
- Feb 16, 2024
2018 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Research Institute (CRI) | Los Angeles | California | 90027 | — |
| University of California San Francisco (UCSF) | San Francisco | California | 94115 | — |
| Boca Raton Regional Hospital (BRRH) | Boca Raton | Florida | 33486 | — |
| ASCLEPES Research Center(ARC) | Weeki Wachee | Florida | 34607 | — |
| Saint Luke's Cancer Institute(SLCI) | Kansas City | Kansas | 64111 | — |
| University of Kansas Medical Center(KUMC) | Kansas City | Kansas | 66160 | — |
| Anne Arundel Health System Research Institute (AAHS) | Annapolis | Maryland | 21401 | — |
| Massachusetts General Hospital(MGH) | Boston | Massachusetts | 02114 | — |
| Michigan Center of Medical Research(MCMR) | Farmington Hills | Michigan | 48334 | — |
| Metro-Minnesota Community Oncology Research Consortium (MMCORC) | Minneapolis | Minnesota | 55426 | — |
| Nevada Cancer Research Foundation (NCRF) | Las Vegas | Nevada | 89106 | — |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03326102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03326102 live on ClinicalTrials.gov.